Literature DB >> 33569048

Regulated Tristetraprolin Overexpression Dampens the Development and Pathogenesis of Experimental Autoimmune Uveitis.

Biying Xu1, Jihong Tang1, Cancan Lyu1, Wambui S Wandu1, Deborah J Stumpo2, Mary J Mattapallil1, Reiko Horai1, Igal Gery1, Perry J Blackshear2,3, Rachel R Caspi1.   

Abstract

Non-infectious uveitis, a common cause of blindness in man, is often mediated by autoimmunity, a process in which cytokines play major roles. The biosynthesis and secretion of pro-inflammatory cytokines are regulated in part by tristetraprolin (TTP), an endogenous anti-inflammatory protein that acts by binding directly to specific sequence motifs in the 3'-untranslated regions of target mRNAs, promoting their turnover, and inhibiting synthesis of their encoded proteins. We recently developed a TTP-overexpressing mouse (TTPΔARE) by deleting an AU-rich element (ARE) instability motif from the TTP mRNA, resulting in increased accumulation of TTP mRNA and protein throughout the animal. Here, we show that homozygous TTPΔARE mice are resistant to the induction of experimental autoimmune uveitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP), an established model for human autoimmune (noninfectious) uveitis. Lymphocytes from TTPΔARE mice produced lower levels of the pro-inflammatory cytokines IFN-γ, IL-17, IL-6, and TNFα than wild type (WT) mice. TTPΔARE mice also produced lower titers of antibodies against the uveitogenic protein. In contrast, TTPΔARE mice produced higher levels of the anti-inflammatory cytokine IL-10, and had higher frequencies of regulatory T-cells, which, moreover, displayed a moderately higher per-cell regulatory ability. Heterozygous mice developed EAU and associated immunological responses at levels intermediate between homozygous TTPΔARE mice and WT controls. TTPΔARE mice were able, however, to develop EAU following adoptive transfer of activated WT T-cells specific to IRBP peptide 651-670, and naïve T-cells from TTPΔARE mice could be activated by antibodies to CD3/CD28. Importantly, TTPΔARE antigen presenting cells were significantly less efficient compared to WT in priming naïve T cells, suggesting that this feature plays a major role in the dampened immune responses of the TTPΔARE mice. Our observations demonstrate that elevated systemic levels of TTP can inhibit the pathogenic processes involved in EAU, and suggest the possible use of TTP-based treatments in humans with uveitis and other autoimmune conditions.
Copyright © 2021 Xu, Tang, Lyu, Wandu, Stumpo, Mattapallil, Horai, Gery, Blackshear and Caspi.

Entities:  

Keywords:  IFNγ; IL-17; autoimmunity; experimental autoimmune uveitis (EAU); immunoregulation, tristetraprolin (TTP); inflammatory cytokine

Year:  2021        PMID: 33569048      PMCID: PMC7868398          DOI: 10.3389/fimmu.2020.583510

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  38 in total

Review 1.  Proliferative assays for T cell function.

Authors:  Ada M Kruisbeek; Ethan Shevach; Angela M Thornton
Journal:  Curr Protoc Immunol       Date:  2004-05

Review 2.  Regulatory T cells and immune tolerance.

Authors:  Shimon Sakaguchi; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono
Journal:  Cell       Date:  2008-05-30       Impact factor: 41.582

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response.

Authors:  B Sun; L V Rizzo; S H Sun; C C Chan; B Wiggert; R L Wilder; R R Caspi
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

5.  Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts.

Authors:  Wi S Lai; Joel S Parker; Sherry F Grissom; Deborah J Stumpo; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Authors:  Zhi-Wei Lai; Ryan Kelly; Thomas Winans; Ivan Marchena; Ashwini Shadakshari; Julie Yu; Maha Dawood; Ricardo Garcia; Hajra Tily; Lisa Francis; Stephen V Faraone; Paul E Phillips; Andras Perl
Journal:  Lancet       Date:  2018-03-15       Impact factor: 79.321

7.  Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin.

Authors:  E Carballo; W S Lai; P J Blackshear
Journal:  Science       Date:  1998-08-14       Impact factor: 47.728

Review 8.  Tristetraprolin as a Therapeutic Target in Inflammatory Disease.

Authors:  Sonika Patial; Perry J Blackshear
Journal:  Trends Pharmacol Sci       Date:  2016-08-05       Impact factor: 14.819

9.  Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product.

Authors:  Elodie Touchard; Romain Benard; Karine Bigot; Jean-Denis Laffitte; Ronald Buggage; Thierry Bordet; Francine Behar-Cohen
Journal:  J Control Release       Date:  2018-08-01       Impact factor: 9.776

10.  Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.

Authors:  Wambui S Wandu; Cuiyan Tan; Osato Ogbeifun; Barbara P Vistica; Guangpu Shi; Samuel J H Hinshaw; Chengsong Xie; Xi Chen; Dennis M Klinman; Huaibin Cai; Igal Gery
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.